EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Bimatoprost SR for Glaucoma Therapy Implanted at the Slit-Lamp in a Real-World Setting

Arsalan Akbar Ali, Denisse Avilés Elescano, Davinder S Grover

Clinical Ophthalmology · 2024-05 · Volume 18 · 1371-1377

DOI: 10.2147/opth.s450220 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Ophthalmology, 2024-05. Verfasst von Arsalan Akbar Ali und 2 weiteren Autor:innen. Beteiligte Einrichtung: Anne Burnett Marion School of Medicine, Texas Christian University, Fort Worth, TX, USA. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To characterize clinical outcomes following a single administration of bimatoprost SR in eyes with glaucoma in a real-world setting implanted at the slit-lamp.

Setting

Tertiary care Glaucoma practice, Glaucoma Associates of Texas, Dallas, Texas.

Design

Retrospective interventional case series.

Methods

Data were analyzed from consecutive patients receiving a single bimatoprost SR implant from the time of its approval to the time of data collection. All eyes were implanted at the slit-lamp. Eyes with less than 1 month of follow-up were excluded. The primary outcome was median time to next intraocular pressure (IOP)-lowering intervention. Mean IOP and medication use, and changes from baseline, were also assessed through 12 months of follow-up.

Results

Overall 129 eyes of 81 patients were analyzed. Following bimatoprost SR administration (replacing a topical prostaglandin analogue [PGA] in most eyes), the median survival time without any further IOP-lowering interventions was between 6-9 months. Mean IOP remained unchanged from baseline at month 1 (consistent with switch from topical to intracameral PGA therapy) and began to rise at month 3. At month 12, 40.5% of eyes (52 eyes) remained intervention-free, mean medication reduction was 0.5 medications per eye, and 27.8% of eyes (36 eyes) were medication-free. Adverse events were uncommon and most were transient and resolved with or without intervention.

Conclusion

This real-world analysis of bimatoprost SR use for glaucoma therapy complements Phase 3 study findings and demonstrates that the implant can safely provide medication reduction through 6 months in most eyes and through 12 months in almost 40% of eyes.

Schlagwörter

Stichwörter der Autor:innen

bimatoprost SRdurystaglaucomasustained release

Autor:innen und Institutionen

  • Anne Burnett Marion School of Medicine, Texas Christian University, Fort Worth, TX, USA.
  • Universidad San Martin de Porres (USMP), Lima, Peru.
  • Glaucoma Associates of Texas, Dallas, TX, USA.

Zitieren

APA

Ali, A. A., Avilés Elescano, D., & Grover, D. S. (2024). Bimatoprost SR for Glaucoma Therapy Implanted at the Slit-Lamp in a Real-World Setting. Clinical Ophthalmology, Volume 18, 1371-1377. https://doi.org/10.2147/opth.s450220

Vancouver

Ali AA, Avilés Elescano D, Grover DS. Bimatoprost SR for Glaucoma Therapy Implanted at the Slit-Lamp in a Real-World Setting. Clinical Ophthalmology. 2024;Volume 18:1371-1377. doi:10.2147/opth.s450220

BibTeX
@article{Ali2024,
  author = {Ali, Arsalan Akbar and Avilés Elescano, Denisse and Grover, Davinder S},
  title = {Bimatoprost SR for Glaucoma Therapy Implanted at the Slit-Lamp in a Real-World Setting},
  journal = {Clinical Ophthalmology},
  year = {2024},
  volume = {Volume 18},
  pages = {1371--1377},
  doi = {10.2147/opth.s450220}
}
Kostenlos starten →